SOURCE: Entelos, Inc.

August 24, 2005 16:59 ET

Entelos Publication in Immunity Reveals Potential Reasons for Type 1 Diabetes Drug Failures

FOSTER CITY, CA -- (MARKET WIRE) -- August 24, 2005 -- Entelos, Inc. announced today the results of a comprehensive analysis of interventions tested in the non-obese diabetic (NOD) mouse model, the primary animal model used to study type 1 diabetes. In a peer-reviewed article published today in the journal Immunity(1), Entelos scientists and their co-authors reveal that some commonly held tenets regarding treatments in the NOD mouse model were not supported by their findings, and that discrepancies in dosing, formulation, and timing could potentially account for the failure of many clinically tested type 1 diabetes therapies.

The article was written by scientists from Entelos, the University of Florida, University of California, San Francisco, University of Colorado Health Sciences Center, Harvard Medical School, University of Massachusetts Medical School, and the American Diabetes Association.

"This is the first time that data from all of these type 1 diabetes therapies were brought together and compared in a unique, insightful manner," said Mikhail Gishizky, Chief Scientific Officer of Entelos. "Results show that contrary to common belief, not all therapies are in fact efficacious in the NOD mouse model. Our team also found that treatments administered early in the disease process had similar effects as those administered later, and that several therapies were even able to treat overtly diabetic mice. This analysis suggests that a more complete analysis of preclinical results may substantially minimize the risks associated with translating preclinical successes to human clinical practice."

These insights were uncovered, and unique approaches developed, during creation of the Type 1 Diabetes PhysioLab® platform, which was developed in collaboration with the American Diabetes Association. The goals of this Collaboration are to advance the understanding of type 1 diabetes pathogenesis using predictive mathematical models, and improve the rationale for advancing potential therapies from preclinical studies into human clinical trials.

About Type 1 Diabetes

Estimates are that as many as one million or more Americans have type 1 diabetes, an immune-mediated disease that leads to destruction of the insulin-producing beta cells in the pancreas and the need for daily insulin injections throughout life. Type 1 diabetes usually arises in children or young adults. Scientific understanding of this disease in humans has been limited by the difficulty of identifying those people likely to develop the disease as well as practical considerations in studying humans with the condition. At this time there are no preventative treatments available for type 1 diabetes.

About Entelos

Entelos, Inc. ( is a biopharmaceutical company focused on discovering and developing new therapies for metabolic and inflammatory disorders. Our mission is to leverage our unique predictive capability in human biology to dramatically improve how medicines are discovered, developed, and brought to market. Using our proprietary PhysioLab biosimulation platforms -- computer-based mathematical models of human disease, we systematically uncover the biological mechanisms underlying a disease in order to identify potential points of therapeutic intervention and the patients most likely to benefit. In addition to our internal research programs, Entelos partners with pharmaceutical and biotechnology organizations worldwide.

Entelos and PhysioLab are registered trademarks and/or service marks of Entelos, Inc.

All other trademarks are the property of their registered owners.

(1) Shoda, L.K., Young, D.L. et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23(2), 115-126.

Contact Information